Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: Rhythm Pharmaceuticals, Inc.

Market Cap 6.63B 5.78B 5.33B 5.01B 9.38B 625B 9.44B 63.39B 24.62B 308B 24.9B 24.36B 1,068B P/E 2026 *
-30.2x
P/E 2027 * -150x
Enterprise Value 6.35B 5.54B 5.1B 4.8B 8.98B 599B 9.04B 60.71B 23.58B 295B 23.84B 23.33B 1,023B EV / Sales 2026 *
21.3x
EV / Sales 2027 * 11.6x
Free-Float
95.77%
Yield 2026 *
-
Yield 2027 * -
Jun. 17 Rhythm Pharmaceuticals, Inc. - Special Call
Jun. 13 Rhythm Pharmaceuticals Presents Interim Six-Month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome CI
Jun. 08 Rhythm Pharmaceuticals, Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-08-2026 01:20 PM
May. 28 Rhythm Pharmaceuticals Publishes New Bardet-Biedl Syndrome Diagnostic Algorithm in the American Journal of Medical Genetics CI
May. 13 Rhythm Pharmaceuticals, Inc. Presents at Bank of America Global Healthcare Conference 2026, May-13-2026 03:00 PM
May. 05 Rhythm Pharmaceuticals, Inc., Q1 2026 Earnings Call, May 05, 2026
May. 05 Rhythm Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
May. 05 Earnings Flash (RYTM) Rhythm Pharmaceuticals, Inc. Reports Q1 Revenue $60.1M, vs. FactSet Est of $55.8M MT
May. 04 Rhythm Pharmaceuticals announces new data presentations in acquired hypothalamic obesity at Pediatric Endocrine Society RE
May. 04 Rhythm Pharmaceuticals Announces New Data Presentations for Setmelanotide in Pediatric Patients with Acquired Hypothalamic Obesity CI
May. 01 Rhythm Pharmaceuticals, Inc. Announces IMCIVREE (Setmelanotide) Granted Marketing Authorization By European Commission For Treatment Of Obesity And Control Of Hunger In Patients With Acquired Hypothalamic Obesity CI
Apr. 07 RBC Capital Adjusts Price Target on Rhythm Pharmaceuticals to $136 From $130, Maintains Outperform Rating MT
Apr. 03 Rhythm Pharmaceuticals, Inc. Announces Changes in Board of Directors, Effective on April 1, 2026 CI

Last Transcript: Rhythm Pharmaceuticals, Inc.

Manager TitleAgeSince
Chief Executive Officer 71 2020-07-19
Chief Executive Officer 58 2020-03-27
Chief Tech/Sci/R&D Officer 46 2016-12-31
Director TitleAgeSince
Director/Board Member 69 2015-03-31
Chairman 71 2017-04-10
Director/Board Member 71 2015-10-31
Change 5-day change 1-year change 3-year change Capi.($)
+1.99%+3.36% - - 6.63B
-1.21%-5.37%+39.94%+145.38% 980B
-2.48%-4.17%+51.52%+39.07% 550B
-2.14%-3.68%+16.71%+56.15% 382B
-1.18%+0.25%+25.86%+16.53% 317B
-2.36%-3.12%+24.71%+11.59% 270B
-2.45%-2.88%+24.29%+30.06% 269B
-1.91%-0.87%-41.95%-49.25% 191B
-1.19%-4.65%+16.56%+47.00% 182B
-1.35%-1.68%+14.59%+56.94% 154B
Average -1.81%-2.68%+19.14%+39.27% 366B
Weighted average by Cap. -1.77%-3.38%+28.08%+63.68%

Financials

2026 *2027 *
Net sales 298M 260M 239M 225M 421M 28.09B 424M 2.85B 1.11B 13.84B 1.12B 1.09B 47.99B 539M 470M 433M 407M 762M 50.82B 767M 5.15B 2B 25.04B 2.02B 1.98B 86.81B
Net income -216M -188M -173M -163M -305M -20.35B -307M -2.06B -801M -10.03B -810M -793M -34.76B -33M -28.75M -26.5M -24.93M -46.64M -3.11B -46.96M -315M -122M -1.53B -124M -121M -5.31B
Net Debt -281M -244M -225M -212M -397M -26.45B -399M -2.68B -1.04B -13.03B -1.05B -1.03B -45.17B -395M -344M -317M -298M -558M -37.22B -562M -3.77B -1.47B -18.34B -1.48B -1.45B -63.58B
Logo Rhythm Pharmaceuticals, Inc.
Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company's lead asset, IMCIVREE, is an MC4R agonist designed to treat hyperphagia and severe obesity, is approved by the Food and Drug Administration (FDA) to reduce excess body weight and maintain reduction long term in adults and pediatric patients aged four years and older with acquired hypothalamic obesity, adult and pediatric patients two years of age and older with syndromic or monogenic obesity due to Bardet-Biedl syndrome (BBS) or genetically confirmed pro-opiomelanocortin (POMC), including proprotein convertase subtilisin/kexin type 1 (PCSK1), deficiency or leptin receptor (LEPR) deficiency. In addition to it the Company is advancing a broad clinical development program for setmelanotide in other rare diseases, as well as investigational MC4R agonists bivamelagon and RM-718, and a preclinical suite of small molecules for the treatment of congenital hyperinsulinism.
Employees
-
Date Price Change
26-06-16 77.00 +1.99%
26-06-11 75.50 -0.66%
26-06-10 76.00 +2.01%
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
CCC
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
96.79USD
Average target price
139.47USD
Spread / Average Target
+44.09%

Quarterly revenue - Rate of surprise

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!